Latest news with #Waterdrop
Yahoo
11 hours ago
- Business
- Yahoo
Origin Materials And 2 Additional Promising Penny Stocks
The U.S. stock market has been riding a wave of optimism, with the S&P 500 recently hitting new highs amid positive trade deal developments and anticipation of earnings reports from major companies. In such a buoyant market, investors often look beyond the large-cap stocks to explore opportunities in smaller segments like penny stocks. While "penny stocks" might seem like an outdated term, they still represent a vibrant area for investment, offering potential growth at lower price points when backed by strong financials. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.67 $614.83M ★★★★★★ CuriosityStream (CURI) $4.60 $258.53M ★★★★★★ WM Technology (MAPS) $0.9931 $161.13M ★★★★★★ Perfect (PERF) $2.51 $266.84M ★★★★★★ Tuniu (TOUR) $0.9326 $101.15M ★★★★★★ Safe Bulkers (SB) $4.14 $416.4M ★★★★☆☆ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.8009 $6.14M ★★★★★★ Lifetime Brands (LCUT) $4.65 $103.33M ★★★★★☆ Tandy Leather Factory (TLF) $3.44 $28.6M ★★★★★★ Click here to see the full list of 415 stocks from our US Penny Stocks screener. Let's explore several standout options from the results in the screener. Origin Materials Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Origin Materials, Inc. operates as a carbon-negative materials company and has a market cap of approximately $89.61 million. Operations: The company generates revenue from its Specialty Chemicals segment, which amounted to $29.89 million. Market Cap: $89.61M Origin Materials, Inc. presents a mixed picture for investors interested in penny stocks. The company has successfully reduced its debt to equity ratio from 44.8% to 1.1% over five years and maintains more cash than total debt, indicating financial prudence. However, it remains unprofitable with a negative return on equity of -30.59%, and earnings have declined significantly over the past five years by 26.6% annually. Despite this, Origin's short-term assets comfortably cover both short- and long-term liabilities, providing some financial stability amidst high share price volatility and an inexperienced board with an average tenure of 2.2 years. Unlock comprehensive insights into our analysis of Origin Materials stock in this financial health report. Learn about Origin Materials' historical performance here. Cassava Sciences Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing drugs for neurodegenerative diseases, with a market cap of approximately $111.11 million. Operations: Cassava Sciences, Inc. currently does not report any revenue segments. Market Cap: $111.11M Cassava Sciences, Inc. offers a complex profile for penny stock investors. Despite being pre-revenue with no significant income streams, the company is debt-free and has short-term assets of US$120.2 million that exceed both its short- and long-term liabilities, indicating some financial resilience. However, it faces challenges such as increased losses over five years at 27.4% annually and less than a year of cash runway if its free cash flow continues to decrease at historical rates. Recent index reclassifications highlight volatility in investor sentiment as it shifts from growth to value benchmarks amidst ongoing strategic changes. Click here and access our complete financial health analysis report to understand the dynamics of Cassava Sciences. Assess Cassava Sciences' previous results with our detailed historical performance reports. OraSure Technologies Simply Wall St Financial Health Rating: ★★★★★★ Overview: OraSure Technologies, Inc. develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices globally with a market cap of $243.10 million. Operations: The company's revenue primarily comes from its Diagnostics and Molecular Solutions segment, totaling $161.63 million. Market Cap: $243.1M OraSure Technologies, Inc. presents a mixed picture for penny stock investors. The company is unprofitable but has managed to reduce its losses over the past five years by 18.8% annually. Its short-term assets of US$313.8 million comfortably cover both short- and long-term liabilities, suggesting financial stability without any debt burden. Recent developments include the launch of HEMAcollect™ PROTEIN for proteomic research and its addition to the Russell 2000 indices, indicating market recognition despite ongoing challenges with profitability and declining revenues from US$54.13 million to US$29.93 million year-over-year in Q1 2025 results. Click to explore a detailed breakdown of our findings in OraSure Technologies' financial health report. Gain insights into OraSure Technologies' future direction by reviewing our growth report. Next Steps Embark on your investment journey to our 415 US Penny Stocks selection here. Contemplating Other Strategies? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ORGN SAVA and OSUR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
4 days ago
- Business
- Yahoo
3 Penny Stocks With Market Caps Over $70M Worth Watching
Over the last 7 days, the market has remained flat, while in the past 12 months it has risen by 14%, with earnings expected to grow by 15% per annum over the next few years. For investors willing to explore beyond established names, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities. Although "penny stocks" might seem like an outdated term, their potential for growth and affordability remains significant, especially when these companies boast strong financials and balance sheet resilience. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.70 $524.41M ★★★★★★ CuriosityStream (CURI) $4.46 $249.3M ★★★★★★ WM Technology (MAPS) $0.9714 $159.1M ★★★★★★ Perfect (PERF) $2.37 $234.25M ★★★★★★ Tuniu (TOUR) $0.9326 $100.29M ★★★★★★ Safe Bulkers (SB) $4.13 $414.36M ★★★★☆☆ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.83 $6.01M ★★★★★★ Lifetime Brands (LCUT) $4.68 $99.74M ★★★★★☆ North European Oil Royalty Trust (NRT) $4.96 $43.75M ★★★★★★ Click here to see the full list of 417 stocks from our US Penny Stocks screener. Let's review some notable picks from our screened stocks. Zura Bio Simply Wall St Financial Health Rating: ★★★★★★ Overview: Zura Bio Limited is a clinical-stage biotechnology company focused on developing medicines for immune and inflammatory disorders in the United States, with a market cap of $79.82 million. Operations: No revenue segments have been reported. Market Cap: $79.82M Zura Bio, a clinical-stage biotechnology company with a market cap of US$79.82 million, is currently pre-revenue, highlighting its early development stage. The recent appointment of Eric Hyllengren as CFO brings extensive financial leadership experience from the biotech sector, potentially strengthening Zura's strategic finance and operational execution. Despite having no debt and sufficient cash runway for over three years, the company's shares are highly volatile and it faces challenges such as being dropped from several growth benchmarks while being added to value indices. Its ongoing Phase 2 trial for tibulizumab reflects active efforts in drug development amidst these transitions. Click here to discover the nuances of Zura Bio with our detailed analytical financial health report. Examine Zura Bio's earnings growth report to understand how analysts expect it to perform. Nextdoor Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Nextdoor Holdings, Inc. operates a neighborhood network that connects neighbors, businesses, and public agencies both in the United States and internationally, with a market cap of approximately $696.31 million. Operations: The company generates revenue of $248.31 million from its Internet Information Providers segment. Market Cap: $696.31M Nextdoor Holdings, Inc., with a market cap of US$696.31 million, trades significantly below its estimated fair value and remains debt-free. Despite being unprofitable with a negative return on equity and no forecasted profitability in the next three years, the company maintains sufficient cash runway for over three years without significant shareholder dilution recently. Recent developments include a major redesign of its platform to enhance user engagement through features like Alerts, News, and Faves. Additionally, Nextdoor has expanded advertising into Canada and completed a substantial share buyback program aimed at enhancing shareholder value. Unlock comprehensive insights into our analysis of Nextdoor Holdings stock in this financial health report. Understand Nextdoor Holdings' earnings outlook by examining our growth report. Elite Pharmaceuticals Simply Wall St Financial Health Rating: ★★★★★★ Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals, with a market cap of approximately $567.50 million. Operations: The company's revenue is primarily derived from its Abbreviated New Drug Applications (ANDA) segment, which generated $84.04 million. Market Cap: $567.5M Elite Pharmaceuticals, Inc., with a market cap of US$567.50 million, has shown revenue growth to US$84.04 million for the year ended March 31, 2025, despite reporting a net loss of US$4.31 million compared to the previous year's net income. The company maintains financial stability with short-term assets exceeding both short and long-term liabilities and has reduced its debt-to-equity ratio significantly over five years. Although unprofitable, Elite's operating cash flow covers its debt well and it hasn't seen meaningful shareholder dilution recently. However, significant insider selling in recent months could be a concern for potential investors. Dive into the specifics of Elite Pharmaceuticals here with our thorough balance sheet health report. Review our historical performance report to gain insights into Elite Pharmaceuticals' track record. Where To Now? Explore the 417 names from our US Penny Stocks screener here. Searching for a Fresh Perspective? AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ZURA KIND and ELTP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
July 2025's Top Penny Stocks To Watch
In the last week, the market has been flat, but it is up 12% over the past year with earnings expected to grow by 15% per annum over the next few years. Penny stocks, often smaller or newer companies, can offer a unique blend of affordability and growth potential when backed by strong financials. This article will explore several penny stocks that stand out for their financial strength and potential for long-term success in today's evolving market landscape. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.45 $517.18M ★★★★★★ CuriosityStream (CURI) $4.32 $252.76M ★★★★★★ WM Technology (MAPS) $0.946 $153.53M ★★★★★★ Perfect (PERF) $2.30 $240.36M ★★★★★★ Tuniu (TOUR) $0.9326 $100.42M ★★★★★★ Safe Bulkers (SB) $4.05 $410.26M ★★★★☆☆ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.82788 $5.93M ★★★★★☆ Lifetime Brands (LCUT) $4.45 $102.66M ★★★★★☆ North European Oil Royalty Trust (NRT) $4.76 $44.48M ★★★★★★ Click here to see the full list of 420 stocks from our US Penny Stocks screener. Let's review some notable picks from our screened stocks. Blade Air Mobility Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Blade Air Mobility, Inc. offers air transportation and logistics services primarily for hospitals both in the United States and internationally, with a market cap of $334.60 million. Operations: The company generates revenue from two main segments: Medical services, contributing $146.74 million, and Passenger services, accounting for $104.75 million. Market Cap: $334.6M Blade Air Mobility, Inc., with a market cap of US$334.60 million, operates in the air transportation and logistics sector, generating significant revenue from medical (US$146.74 million) and passenger services (US$104.75 million). Despite being unprofitable with increasing losses over the past five years, Blade remains debt-free and has a cash runway exceeding three years based on current free cash flow. The company's short-term assets comfortably cover both short- and long-term liabilities. Recent earnings reports show improved sales of US$54.31 million for Q1 2025 compared to the previous year, alongside a reduced net loss of US$3.49 million. Dive into the specifics of Blade Air Mobility here with our thorough balance sheet health report. Gain insights into Blade Air Mobility's future direction by reviewing our growth report. MoneyHero Simply Wall St Financial Health Rating: ★★★★★☆ Overview: MoneyHero Limited operates a personal finance aggregation and comparison platform for banking, insurance, and other financial products, with a market cap of $53.14 million. Operations: The company's revenue is primarily generated from its operations in Hong Kong ($29.12 million), Singapore ($27.03 million), the Philippines ($10.64 million), and Taiwan ($4.79 million). Market Cap: $53.14M MoneyHero Limited, with a market cap of US$53.14 million, operates a personal finance platform across Asia. Despite being unprofitable and experiencing increased losses over the past five years, the company remains debt-free and has sufficient short-term assets to cover liabilities. Recent earnings reports show a decrease in sales to US$14.31 million for Q1 2025 from US$22.18 million the previous year, but net losses have narrowed significantly. A strategic partnership with RCBC Bankard Services Corporation aims to enhance its credit card offerings in the Philippines, potentially bolstering its position in digital financial services within the region. Jump into the full analysis health report here for a deeper understanding of MoneyHero. Understand MoneyHero's earnings outlook by examining our growth report. Offerpad Solutions Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Offerpad Solutions Inc., along with its subsidiaries, offers technology-driven solutions for the U.S. residential real estate market and has a market cap of $47.38 million. Operations: The company generates revenue primarily through its Cash Offer segment, which accounted for $770.72 million. Market Cap: $47.38M Offerpad Solutions Inc., with a market cap of US$47.38 million, is navigating challenges in the U.S. residential real estate market. Despite generating significant revenue through its Cash Offer segment, recent earnings showed a decline to US$160.7 million in Q1 2025 from US$285.36 million the previous year, with net losses narrowing slightly. The company has been dropped from multiple Russell indexes as of June 2025, reflecting potential investor concerns about its financial stability and growth prospects. However, Offerpad's strategic initiatives like HomePro and partnerships aim to enhance customer engagement and expand its service offerings despite ongoing unprofitability challenges. Get an in-depth perspective on Offerpad Solutions' performance by reading our balance sheet health report here. Explore Offerpad Solutions' analyst forecasts in our growth report. Where To Now? Unlock more gems! Our US Penny Stocks screener has unearthed 417 more companies for you to here to unveil our expertly curated list of 420 US Penny Stocks. Contemplating Other Strategies? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BLDE MNY and OPAD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
6 days ago
- Business
- Yahoo
3 Promising Penny Stocks With Market Caps Over $40M
The U.S. stock market has been navigating a period of volatility, with major indices such as the Dow Jones Industrial Average and the S&P 500 experiencing fluctuations amid geopolitical tensions and economic policy discussions. Despite these broader market challenges, penny stocks remain an intriguing area for investors, representing smaller or newer companies that can offer potential value when backed by strong financials. In this context, we explore three penny stocks that exhibit financial robustness and growth potential, highlighting their promise in delivering opportunities for investors seeking to uncover hidden gems in the market. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.43 $528.03M ★★★★★★ CuriosityStream (CURI) $4.38 $253.92M ★★★★★★ WM Technology (MAPS) $0.9129 $162.49M ★★★★★★ Perfect (PERF) $2.36 $232.21M ★★★★★★ Tuniu (TOUR) $0.9326 $100.94M ★★★★★★ Safe Bulkers (SB) $4.01 $417.42M ★★★★☆☆ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.81645 $6.03M ★★★★★☆ Lifetime Brands (LCUT) $4.58 $104.9M ★★★★★☆ North European Oil Royalty Trust (NRT) $4.84 $44.39M ★★★★★★ Click here to see the full list of 426 stocks from our US Penny Stocks screener. Let's dive into some prime choices out of the screener. Burning Rock Biotech Simply Wall St Financial Health Rating: ★★★★★★ Overview: Burning Rock Biotech Limited focuses on developing and selling cancer therapy selection tests in China, with a market cap of $49.85 million. Operations: Burning Rock Biotech generates revenue through its In-Hospital Channel (CN¥224.79 million), Central Laboratory Channel (CN¥166.33 million), and Pharma Research and Development Channel (CN¥132.16 million). Market Cap: $49.85M Burning Rock Biotech, with a market cap of US$49.85 million, reported first-quarter sales of CN¥133.08 million, up from CN¥125.62 million a year earlier, while reducing its net loss significantly to CN¥13.5 million from CN¥121.55 million. Despite being unprofitable, it has shown progress in reducing losses over five years and benefits from an experienced management team with an average tenure of 9.3 years. The company is debt-free and possesses sufficient cash runway for over three years based on current free cash flow levels, although its share price remains highly volatile compared to other U.S.-listed stocks. Dive into the specifics of Burning Rock Biotech here with our thorough balance sheet health report. Gain insights into Burning Rock Biotech's historical outcomes by reviewing our past performance report. loanDepot Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: loanDepot, Inc. operates in the United States by originating, financing, selling, and servicing residential mortgage loans with a market cap of approximately $501.46 million. Operations: The company generates revenue primarily from the originating, financing, and selling of mortgage loans, amounting to $1.09 billion. Market Cap: $501.46M loanDepot, Inc., with a market cap of US$501.46 million, recently joined multiple Russell indexes, potentially increasing its visibility among investors. Despite a high net debt to equity ratio and ongoing unprofitability with a negative return on equity, the company has not diluted shareholders significantly over the past year. Its short-term assets of US$4.5 billion cover both short- and long-term liabilities, providing some financial stability amidst challenges. Earnings are forecasted to grow substantially at 112.47% annually, yet its current losses have increased by 43.4% per year over five years, reflecting ongoing financial hurdles despite good relative value compared to peers. Take a closer look at loanDepot's potential here in our financial health report. Learn about loanDepot's future growth trajectory here. NameSilo Technologies Simply Wall St Financial Health Rating: ★★★★★☆ Overview: NameSilo Technologies Corp. operates through its subsidiaries to offer domain name registration services across the United States, various regions in Asia, Australasia, and internationally, with a market cap of $77.37 million. Operations: The company generates revenue primarily from Domain Registration and Related Services, amounting to CA$58.30 million. Market Cap: $77.37M NameSilo Technologies, with a market cap of CA$77.37 million, has shown revenue growth, reporting CA$15.87 million for Q1 2025 compared to CA$12.8 million a year prior. Despite this, the company faces financial challenges as its short-term assets of CA$32.6 million do not cover liabilities of CA$45.9 million, and it remains unprofitable with negative return on equity at 38.43%. However, it has reduced its debt-to-equity ratio significantly over five years and holds more cash than total debt, offering some financial resilience despite auditor concerns about its ability to continue as a going concern. Get an in-depth perspective on NameSilo Technologies' performance by reading our balance sheet health report here. Review our historical performance report to gain insights into NameSilo Technologies' track record. Turning Ideas Into Actions Navigate through the entire inventory of 426 US Penny Stocks here. Ready For A Different Approach? Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BNR LDI and URLO.F. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
10-07-2025
- Business
- Yahoo
Top Penny Stocks To Watch In July 2025
In the last week, the market has been flat, but it is up 12% over the past year, with earnings expected to grow by 15% per annum over the next few years. Investing in penny stocks—though often seen as a niche area—can still offer growth opportunities, particularly when these stocks are supported by strong financial health. As we explore several penny stocks today, we'll focus on those that combine balance sheet strength with long-term potential. Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.42 $517.18M ★★★★★★ WM Technology (MAPS) $0.9386 $154.96M ★★★★★★ Perfect (PERF) $2.34 $241.38M ★★★★★★ Talkspace (TALK) $2.78 $456.77M ★★★★★★ Tuniu (TOUR) $0.9326 $99.78M ★★★★★★ Safe Bulkers (SB) $3.77 $384.69M ★★★★☆☆ Sequans Communications (SQNS) $2.07 $52.57M ★★★★★★ BAB (BABB) $0.85 $6.17M ★★★★★☆ North European Oil Royalty Trust (NRT) $4.90 $45.95M ★★★★★★ TETRA Technologies (TTI) $3.54 $467.09M ★★★★☆☆ Click here to see the full list of 422 stocks from our US Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates to degrade disease-causing proteins, with a market cap of $121.42 million. Operations: C4 Therapeutics generates its revenue primarily through its Pharmaceuticals segment, which reported $39.78 million. Market Cap: $121.42M C4 Therapeutics, Inc. is navigating a challenging landscape as it remains unprofitable with increasing losses over the past five years. Despite having no debt and short-term assets of US$232.5 million exceeding both short and long-term liabilities, the company faces volatility in its share price and was recently dropped from multiple Russell indices, which may impact investor sentiment. The firm reported a net loss of US$26.32 million for Q1 2025 but has a cash runway for nearly two years if current cash flow trends persist. An increase in authorized shares suggests potential future capital raising activities. Dive into the specifics of C4 Therapeutics here with our thorough balance sheet health report. Learn about C4 Therapeutics' future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Sana Biotechnology, Inc. is a biotechnology company that specializes in developing engineered cells as medicines in the United States, with a market cap of approximately $913.50 million. Operations: Sana Biotechnology, Inc. currently does not report any revenue segments. Market Cap: $913.5M Sana Biotechnology, Inc. is pre-revenue and faces challenges with short-term assets of US$112.7 million not covering long-term liabilities of US$203.2 million, though it has no debt and a seasoned board. Recent volatility in its share price remains high despite a reduction over the past year. The company announced promising six-month results from its UP421 study for type 1 diabetes but faces legal challenges with a class action lawsuit alleging misleading statements about financial stability and product prospects. Sana's inclusion in multiple Russell indices may enhance visibility among investors despite ongoing financial hurdles. Click here to discover the nuances of Sana Biotechnology with our detailed analytical financial health report. Examine Sana Biotechnology's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tuya Inc. operates as an AI cloud platform service provider in the People's Republic of China and internationally, with a market cap of approximately $1.49 billion. Operations: The company's revenue is derived from its Internet Software & Services segment, amounting to $311.64 million. Market Cap: $1.49B Tuya Inc. has shown significant growth, achieving profitability with a net income of US$11.02 million in Q1 2025, compared to a loss the previous year. The company is debt-free, with strong short-term assets of US$913.6 million covering both short and long-term liabilities comfortably. Recent strategic changes include board adjustments and amendments to bylaws for enhanced governance and compliance. Tuya's focus on AIoT innovations through its AI Agent Development Platform positions it well for future opportunities, though its dividend coverage remains weak at 2.4%. The management team is experienced, contributing to stable operations amidst industry competition. Jump into the full analysis health report here for a deeper understanding of Tuya. Assess Tuya's future earnings estimates with our detailed growth reports. Unlock more gems! Our US Penny Stocks screener has unearthed 419 more companies for you to here to unveil our expertly curated list of 422 US Penny Stocks. Searching for a Fresh Perspective? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CCCC SANA and TUYA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
